Clinical Trials Logo

Lewy Body Disease clinical trials

View clinical trials related to Lewy Body Disease.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05778695 Terminated - Parkinson Disease Clinical Trials

Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Ketones

Start date: March 9, 2023
Phase: N/A
Study type: Interventional

Small exploratory open-label pilot study to assess supplementation of a ketone ester (KetoneAid) as a potential therapy for persons with Parkinson disease (PD), Parkinson Disease Dementia/Lewy Body Dementia (PDD/LBD), and healthy controls.

NCT ID: NCT02928445 Terminated - Clinical trials for Dementia With Lewy Bodies

Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension

Start date: October 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This 6-month extension study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) in subjects with Dementia with Lewy bodies (DLB) who have participated in the double-blind, placebo-controlled, lead-in study RVT-101-2001.

NCT ID: NCT02871427 Terminated - Clinical trials for Dementia With Lewy Bodies

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Start date: October 20, 2016
Phase: Phase 2
Study type: Interventional

This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).

NCT ID: NCT02263287 Terminated - Alzheimer Disease Clinical Trials

LESCOD: "Lewy Body Screening in Cognitive Disorders"

LESCOD
Start date: October 2014
Phase: N/A
Study type: Interventional

Dementia with Lewy body (DLB) is the second most common neurodegenerative dementia in autopsy series. However, DLB represents a small proportion of the clinical diagnoses in epidemiology registries. Indeed Alzheimer disease (AD) and DLB are often concomitant, they share many symptoms and only a small weight is given to non-motor symptoms in DLB diagnosis. DLB is at the end of a pathological spectrum overlapping with AD, explaining the poor diagnostic value of both diagnostic criteria. To date there is still a need for a tool able to discriminate patients with pure DLB from those expressing common signs with both AD and DLB and those with pure AD. The purpose of this study is to validate a semi quantitative scale designed to reflect the Lewy Bodies burden in patients with mild to moderate cognitive decline. The investigators hypothesized that the score obtained may differentiate between AD, DLB and patients fulfilling clinical criteria for both DLB an AD. This score could also be correlated with dopaminergic depletion assessed with [18F]fluorodopa PET/computed tomography and/or with potential biomarkers of ADD measured in cerebrospinal fluid. This clinical validation is a preliminary work preceding further studies correlating the LeSCoD score with functional imaging features, prognosis and therapeutic response. Thus, the expected outcomes involve an improvement in demented patients' care, as well as a better patient selection for further therapeutic studies